Genetic Technologies appoints new chief financial officer

Latest News

Molecular diagnostics company Genetic Technologies (ASX:GTG)  has announced the appointment of Michael Tonroe as its new chief financial officer.

Mr Tonroe, who will commence in the role on 28 June, has over 25 years of experience in overseeing the finance function at both management and board-level positions for private and listed companies in Australia, UK, US and Canada. He also has extensive experience in the biotechnology sector across both the financial and company secretary roles having most recently managed both functions for dual-listed Opthea.

Chair Peter Rubinstein said, “We are pleased to appoint Michael to the role of Chief Financial Officer. Michael’s background and expertise in cross border financial management will be a significant asset for GTG. In conjunction with the recent appointment of Simon Morriss we are well-positioned with a strong senior leadership team across all major functions with significant depth of experience and expertise.”

Mr Rubinstein continued, “We thank the team at CFO Solutions for their critical outsourced financial support over the past few years as we repositioned the business and established our longer-term strategy. Their professionalism and expertise have been highly appreciated and we look forward to a smooth transition when Michael commences with us at the end of June.”

Mr Tonroe has previously served as chief financial officer and company secretary of the Australian Synchrotron in Melbourne. He also has extensive accounting expertise having worked for both Deloitte and KPMG in the UK and Hong Kong.

“I am excited to be joining the team at Genetic Technologies. The depth of experience sitting within this business already is impressive and I am thrilled to once again to utilise my skills and expertise in working with companies as they transition from early-stage revenue to full commercialisation. I look forward to working with the whole team to establish the in-house finance function to provide the structure and support for Genetic Technologies long-term strategy,” added Mr Tonroe.